Methotrexate embryopathy in a surviving intrauterine fetus after presumed diagnosis of ectopic pregnancy: case report.
METHODS
A 30-year-old woman with a history of 6 spontaneous first trimester abortions and no living children, who had previously been treated for polycystic ovarian syndrome, was given methotrexate parenterally for a suspected ectopic pregnancy at 5 weeks of amenorrhea. Later, a surviving intrauterine pregnancy was noted, and the pregnancy continued. Her baby was delivered with multiple skeletal anomalies and ambiguous genitalia.


CONCLUSIONS
Physicians must discuss the teratogenicity of methotrexate with their patients before its administration. Careful clinical and ultrasound evaluations are recommended before the administration of methotrexate to avoid complications in pregnancy and adverse birth outcomes.
Addar
Mohammed Hassan
MH
Department of Obstetrics and Gynecology, King Khaled University Hospital, Riyadh, Saudi Arabia.
D000014:Abnormalities, Drug-Induced; D000015:Abnormalities, Multiple / Q000139:chemically induced*; D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D001842:Bone and Bones / Q000002:abnormalities*; D005260:Female; D005837:Genitalia, Male / Q000002:abnormalities*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011271:Pregnancy, Ectopic / Q000188:drug therapy; D013723:Teratogens
D000020:Abortifacient Agents, Nonsteroidal; D013723:Teratogens; D008727:Methotrexate